Lipella Pharmaceuticals announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus, or OLP, patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
Questions or Comments about the article? Write to editor@tipranks.com